Pyxis Oncology, Inc. (NASDAQ:PYXS) Sees Significant Drop in Short Interest

Pyxis Oncology, Inc. (NASDAQ:PYXS) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totalling 2,210,000 shares, a decline of 18.1% from the March 31st total of 2,700,000 shares. Approximately 4.8% of the shares of the stock are sold short. Based on an average daily volume of 909,000 shares, the days-to-cover ratio is currently 2.4 days.

Pyxis Oncology Price Performance

PYXS stock remained flat at $4.30 during trading on Friday. 164,540 shares of the company’s stock traded hands, compared to its average volume of 649,712. Pyxis Oncology has a fifty-two week low of $1.35 and a fifty-two week high of $6.85. The firm has a 50 day simple moving average of $5.10 and a two-hundred day simple moving average of $3.25.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.16. As a group, analysts anticipate that Pyxis Oncology will post -0.85 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Commonwealth Equity Services LLC bought a new position in Pyxis Oncology during the 3rd quarter valued at about $26,000. Acadian Asset Management LLC bought a new position in Pyxis Oncology in the third quarter worth approximately $26,000. Schulhoff & Co. Inc. purchased a new stake in shares of Pyxis Oncology during the 3rd quarter worth $44,000. Radcliffe Capital Management L.P. bought a new stake in shares of Pyxis Oncology in the 3rd quarter valued at about $106,000. Finally, Cable Car Capital LLC purchased a new position in Pyxis Oncology in the fourth quarter worth $111,000. Institutional investors own 39.09% of the company’s stock.

Analyst Ratings Changes

PYXS has been the topic of a number of recent analyst reports. BTIG Research assumed coverage on Pyxis Oncology in a report on Friday, February 9th. They set a “buy” rating and a $8.00 price target on the stock. SVB Leerink initiated coverage on shares of Pyxis Oncology in a research report on Tuesday, January 23rd. They set an “outperform” rating and a $12.00 price objective on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $7.00 target price on shares of Pyxis Oncology in a research note on Friday, March 22nd. Leerink Partnrs reiterated an “outperform” rating on shares of Pyxis Oncology in a research note on Tuesday, January 23rd. Finally, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Wednesday, April 10th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $8.50.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.